| (Values in U.S. Thousands) | Feb, 2018 | Feb, 2017 | Feb, 2016 | Feb, 2015 | Feb, 2014 |
| Sales | 20 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -3,180 | -2,940 | -4,650 | -7,990 | -5,370 |
| Net Income Growth | -8.16% | +36.77% | +41.80% | -48.79% | -113.10% |
Metastat Inc (MTST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
MetaStat, Inc. is a life science company focused on understanding and treating systemic metastasis. The Company's portfolio is comprised of two diagnostic assets - MetaSite(TM) and MenaCalc(TM) and a therapeutic platform - MenaBloc(TM). Its MetaSite Breast(TM) and MenaCalc(TM) diagnostic product lines are designed to predict the probability of cancer metastasizing and MenaBloc therapeutics to reduce or eliminate metastasis. MetaStat, Inc. is headquartered in Montclair, New Jersey.
Fiscal Year End Date: 02/28